Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jul;126(1):83-91.e1.
doi: 10.1016/j.jaci.2010.04.030. Epub 2010 Jun 12.

Oral peanut immunotherapy in children with peanut anaphylaxis

Katharina Blumchen  1 , Helen Ulbricht, Ute Staden, Kerstin Dobberstein, John Beschorner, Lucila Camargo Lopes de Oliveira, Wayne G Shreffler, Hugh A Sampson, Bodo Niggemann, Ulrich Wahn, Kirsten Beyer
Affiliations
Randomized Controlled Trial

Oral peanut immunotherapy in children with peanut anaphylaxis

Katharina Blumchen et al. J Allergy Clin Immunol. 2010 Jul.

Abstract

Background: The only treatment option for peanut allergy is strict avoidance.

Objective: To investigate efficacy and safety of oral immunotherapy (OIT) in peanut allergy.

Methods: Twenty-three children (age, 3.2-14.3 years) with IgE-mediated peanut allergy confirmed by positive double-blind, placebo-controlled food challenge (DBPCFC) received OIT following a rush protocol with roasted peanut for 7 days. If a protective dose of at least 0.5 g peanut was not achieved, patients continued with a long-term buildup protocol using biweekly dose increases up to at least 0.5 g peanut. A maintenance phase for 8 weeks was followed by 2 weeks of peanut avoidance and a final DBPCFC. Immunologic parameters were determined.

Results: After OIT using the rush protocol, patients tolerated a median dose of only 0.15 g peanut. Twenty-two of 23 patients continued with the long-term protocol. After a median of 7 months, 14 patients reached the protective dose. At the final DBPCFC, patients tolerated a median of 1 g (range, 0.25-4 g) in comparison with 0.19 g peanut at the DBPCFC before OIT (range, 0.02-1 g). In 2.6% of 6137 total daily doses, mild to moderate side effects were observed; in 1.3%, symptoms of pulmonary obstruction were detected. OIT was discontinued in 4 of 22 patients because of adverse events. There was a significant increase in peanut-specific serum IgG(4) and a decrease in peanut-specific IL-5, IL-4, and IL-2 production by PBMCs after OIT.

Conclusion: Long-term OIT appears to be safe and of some benefit in many patients with peanut allergy. With an increase in threshold levels and a reduction of peanut-specific T(H)2 cytokine production, the induction of tolerance may be feasible in some patients.

PubMed Disclaimer

Publication types